Document Detail


Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
MedLine Citation:
PMID:  10096977     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Our objective was to study mechanisms for reduced complement activation by heparin coating of cardiopulmonary bypass equipment in clinical heart surgery. METHODS: Adults undergoing elective coronary artery bypass grafting were randomized to cardiopulmonary bypass with Duraflo II heparin-coated (n = 15) or uncoated (n = 14) sets (Duraflo coating surface; Baxter International, Inc, Deerfield, Ill). Blood samples were analyzed with the use of enzyme immunoassays for C1rs-C1 inhibitor complexes and the activation products Bb, C4bc, C3bc, C5a-desArg, and the terminal complement complex. Data were compared by repeated-measures analysis of variance. RESULTS: C1 was activated during bypass, and increases in C1rs-C1 inhibitor complexes were larger with heparin coating (P =.03). C4bc increased after administration of protamine, without intergroup differences (P =.69). Bb (P =.22) and C5a-desArg (P =.13) tended to increase less with heparin coating. Formation of C3bc (P =.03) and the terminal complement complex (P <.01) was significantly reduced with heparin coating. C5a-desArg increased 2-fold during bypass, whereas the terminal complement complex increased 10- to 20-fold. Maximal terminal complement complex concentrations were significantly correlated to maximal Bb and C3bc (R = 0.6, P <.001), but not to C1rs-C1 inhibitor complexes or C4bc (R < 0.05, P >.8). CONCLUSIONS: C1 activation during bypass was increased by heparin coating, but further classical pathway activation was held in check until administration of protamine. Heparin coating significantly inhibited C3bc and terminal complement complex formation. Terminal complement complex concentrations were related to alternative pathway activation and may be useful for evaluation of differences in bypass circuitry. Increases and intergroup differences in terminal complement complex concentrations were much larger than those in C5a-desArg.
Authors:
V Videm; T E Mollnes; K Bergh; E Fosse; B Mohr; T A Hagve; A O Aasen; J L Svennevig
Related Documents :
16077397 - Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during ext...
8329417 - Platelet function after total artificial heart replacement: clinical application and ex...
7998887 - Less platelet damage in the curved vane centrifugal pump: a comparative study with the ...
11493727 - Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical...
23399357 - Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from he...
23368907 - Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule p2y1 antagonists.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  117     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-04-16     Completed Date:  1999-04-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  803-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery A, Institute for Surgical Research, Department of Anaesthesiology, and Department of Clinical Chemistry, The National Hospital, Oslo University, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / administration & dosage*
Biocompatible Materials
Cardiopulmonary Bypass / instrumentation*
Complement Activation*
Complement Pathway, Alternative
Complement Pathway, Classical
Coronary Artery Bypass*
Female
Heparin / administration & dosage*
Humans
Immunoenzyme Techniques
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Biocompatible Materials; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of comp...
Next Document:  Ischemic preconditioning does not acutely improve load-insensitive parameters of contractility in in...